$PTI if we compare our phase 1 data to VRTX phase 2, our market cap should be about $12b. That’s where VRTX was when they were getting their very sloppy and only slightly positive symdeko and Orkambi data (with most treatment groups having NO FEV1 RESPONSE). Their triplet ph2 data last year was cleaner, but they had already figured out the optimal doublet dose over several years. The market somehow expected PTI to get everything perfect at once on their last trial They have a very solid chance this round. At the very least, I expect them to be much closer and the data much cleaner PTI will get a sizable share of the CF market. Just a question of how much. Our share price still has a hell of a lot of catching up to do
  • 18
  • 13